A number of carriers of a human (immunodeficiency virus) may increase by some percent.
A number of carriers of a human (immunodeficiency virus) may lead to (deficiency syndrome).
A drug may minimize a transmission of a human (immunodeficiency virus).
A (vaccine development) can be for a human (immunodeficiency virus).
Some percent of adults may be infected with immunodeficiency.
Acquired (immunodeficiency syndrome) may undergo a division.
Some types of human (immunodeficiency virus) may infect humans.